Filtered By:
Condition: Bleeding
Drug: Warfarin

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 1962 results found since Jan 2013.

Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Front Biosci (Schol Ed). 2022 Jul 21;14(3):21. doi: 10.31083/j.fbs1403021.ABSTRACTThe most frequent arrhythmia treated is atrial fibrillation (AF), which necessitates the use of oral anticoagulants (OACs) to reduce the risk of thromboembolism and stroke. Patients with chronic kidney disease are more likely to develop AF, with a 10% frequency among those on chronic dialysis. Warfarin is the most widely prescribed OAC for individuals with end-stage kidney disease (ESKD). On the other hand, direct OACs (DOACs) are generally safer than warfarin, with fewer fatal bleeding events and a fixed dose that does not require close inte...
Source: Frontiers in Bioscience - Scholar - September 22, 2022 Category: Biomedical Science Authors: Nikolaos Ktenopoulos Marios Sagris Panagiotis Theofilis Sophia Lionaki Loukianos S Rallidis Source Type: research

Long-term outcome and risk factors associated with events in patients with atrial fibrillation treated with oral anticoagulants: The ASSAF-K registry
CONCLUSIONS: This multi-center registry demonstrated the long-term outcome in patients with AF treated with and without OACs and suggests that DOAC therapy is safe and beneficial in hospitals and clinics.PMID:36109256 | DOI:10.1016/j.jjcc.2022.08.012
Source: Journal of Cardiology - September 15, 2022 Category: Cardiology Authors: Yutaka Hatori Hiroyuki Sakai Nobuo Hatori Tomoyuki Kunishima Atsuo Namiki Makoto Shimizu Nobuo Toyosaki Masaomi Kuwajima Naoki Sato ASSAF-K investigators Source Type: research

A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
CONCLUSION: Further studies are still required, some ongoing, in patients with advanced CKD (CrCl < 30 ml/min) to identify the safest and most effective treatment options for VTE and AF.PMID:36006608 | DOI:10.1007/s40620-022-01413-x
Source: Journal of Nephrology - August 25, 2022 Category: Urology & Nephrology Authors: Kathrine Parker John Hartemink Ananya Saha Roshni Mitra Penny Lewis Albert Power Satarupa Choudhuri Sandip Mitra Jecko Thachil Source Type: research